Urbagen gene addition therapy

Phase 2Biologic

CCTNNB1 Foundation

Urbagen gene addition therapy is one of 6 biologic programs targeting Neurodevelopment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeurodevelopmentRecruiting

NeurodevelopmentPhase 2

Recruiting

Competition

Competitive Landscape

7 competitors in Neurodevelopment

#DrugCompanyPhaseTrials

Medrol

Pfizer

Phase 2

1 2

Rapamune

PPrism Pharmaceuticals

Phase 2

1 3

BPN14770

Shionogi

Phase 2

1 4

Urbagen gene addition therapy

CCTNNB1 Foundation

Phase 2

1 5

Recombinant Human Erythropoietin

Amgen

Preclinical

1 6

Vit B12

SSitaram Bhartia Institute of Science and Research

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 1/2Recruiting

Neurodevelopment

NCT07270549

Clinical

Trials by Indication[1]

Neurodevelopment1 trial

Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome

Recruiting·CCTNNB1 Foundation·Phase 1/2·NCT07270549·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Urbagen gene addition therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Urbagen gene addition therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Urbagen gene addition therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CTNNB1 Foundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: CCTNNB1 Foundation

Urbagen gene addition therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Neurodevelopment1 trial

References

Drug Info

Quick Facts

Related News